AMONDYS 45 Drug Patent Profile

When do Amondys 45 patents expire, and what generic alternatives are available?

Amondys 45 is a drug marketed by Sarepta Theraps Inc and is included in one NDA. There are five patents protecting this drug.

This drug has eighty-eight patent family members in twenty-five countries.

The generic ingredient in AMONDYS 45 is casimersen. One supplier is listed for this compound. Additional details are available on the casimersen profile page.

DrugPatentWatch^® Generic Entry Outlook for Amondys 45

Amondys 45 was eligible for patent challenges on February 25, 2025.

By analyzing the patents and regulatory protections it appears that the earliest date for generic entry will be February 25, 2028. This may change due to patent challenges or generic licensing.

There has been one patent litigation case involving the patents protecting this drug, indicating strong interest in generic launch. Recent data indicate that 63% of patent challenges are decided in favor of the generic patent challenger and that 54% of successful patent challengers promptly launch generic drugs.

Indicators of Generic Entry

Summary for AMONDYS 45

International Patents:	88
US Patents:	5
Applicants:	1
NDAs:	1
Finished Product Suppliers / Packagers:	1
Patent Litigation and PTAB cases:	See patent lawsuits and PTAB cases for AMONDYS 45
What excipients (inactive ingredients) are in AMONDYS 45?	AMONDYS 45 excipients list
DailyMed Link:	AMONDYS 45 at DailyMed

DrugPatentWatch^® Estimated Loss of Exclusivity (LOE) Date for AMONDYS 45

Constraining patent/regulatory exclusivity:

TREATMENT OF DUCHENNE MUSCULAR DYSTROPHY (DMD) IN PATIENTS WHO HAVE A CONFIRMED MUTATION OF THE DMD GENE THAT IS AMENABLE TO EXON 45 SKIPPING

NDA:

213026

Dosage:

SOLUTION;INTRAVENOUS

^*The generic entry opportunity date is the latter of the last compound-claiming patent and the last regulatory exclusivity protection. Many factors can influence early or later generic entry. This date is provided as a rough estimate of generic entry potential and should not be used as an independent source.

Pharmacology for AMONDYS 45

Drug Class	Antisense Oligonucleotide
Physiological Effect	Increased Protein Synthesis

US Patents and Regulatory Information for AMONDYS 45

AMONDYS 45 is protected by seven US patents and two FDA Regulatory Exclusivities.

This potential generic entry date is based on TREATMENT OF DUCHENNE MUSCULAR DYSTROPHY (DMD) IN PATIENTS WHO HAVE A CONFIRMED MUTATION OF THE DMD GENE THAT IS AMENABLE TO EXON 45 SKIPPING.

Generics may enter earlier, or later, based on new patent filings, patent extensions, patent invalidation, early generic licensing, generic entry preferences, and other factors.

Applicant	Tradename	Generic Name	Dosage	NDA	Approval Date	TE	Type	RLD	RS	Patent No.	Patent Expiration	Product	Substance	Delist Req.	Exclusivity Expiration
Sarepta Theraps Inc	AMONDYS 45	casimersen	SOLUTION;INTRAVENOUS	213026-001	Feb 25, 2021		RX	Yes	Yes
Sarepta Theraps Inc	AMONDYS 45	casimersen	SOLUTION;INTRAVENOUS	213026-001	Feb 25, 2021		RX	Yes	Yes			Y	Y
Sarepta Theraps Inc	AMONDYS 45	casimersen	SOLUTION;INTRAVENOUS	213026-001	Feb 25, 2021		RX	Yes	Yes			Y	Y
Sarepta Theraps Inc	AMONDYS 45	casimersen	SOLUTION;INTRAVENOUS	213026-001	Feb 25, 2021		RX	Yes	Yes
Sarepta Theraps Inc	AMONDYS 45	casimersen	SOLUTION;INTRAVENOUS	213026-001	Feb 25, 2021		RX	Yes	Yes

Expired US Patents for AMONDYS 45

Applicant	Tradename	Generic Name	Dosage	NDA	Approval Date	Patent No.	Patent Expiration
Sarepta Theraps Inc	AMONDYS 45	casimersen	SOLUTION;INTRAVENOUS	213026-001	Feb 25, 2021
Sarepta Theraps Inc	AMONDYS 45	casimersen	SOLUTION;INTRAVENOUS	213026-001	Feb 25, 2021
Sarepta Theraps Inc	AMONDYS 45	casimersen	SOLUTION;INTRAVENOUS	213026-001	Feb 25, 2021
Sarepta Theraps Inc	AMONDYS 45	casimersen	SOLUTION;INTRAVENOUS	213026-001	Feb 25, 2021

International Patents for AMONDYS 45

See the table below for patents covering AMONDYS 45 around the world.

Country	Patent Number	Title	Estimated Expiration
Australia	2010317599
Australia	2016202924
Australia	2018202105
Australia	2020260498
Australia	2023203103

AMONDYS 45 (casimersen) Market Dynamics and Financial Trajectory: Sales Trend, Pricing, Competitor Risk, and Exclusivity/Patent-Led Entry Timelines

Last updated: June 26, 2026

AMONDYS 45 (casimersen), an exon 45 skipping antisense oligonucleotide for Duchenne muscular dystrophy (DMD) with confirmed mutations amenable to exon 45 skipping, has a commercial profile shaped by ultra-narrow eligibility, hospital/infusion-distribution economics, and strict payer utilization controls. Financial trajectory is driven by patient counts, dose intensity (weekly dosing), and pharmacy benefit management that typically limits access to documented exon 45 mutation carriers. Competitive pressure remains primarily from other DMD exon-skipping therapies and the broader field’s shift toward gene and RNA modalities, rather than immediate same-exon casimersen generics.

What is AMONDYS 45 and how does casimersen fit in the DMD exon-skipping market?

Short answer: AMONDYS 45 is a niche, high-cost weekly infusion therapy for a small DMD subgroup defined by exon 45 amenable mutations.

Casimersen is part of a cluster of DMD exon-skipping treatments built on antisense oligonucleotide chemistry. In market dynamics, casimersen’s core commercial drivers are:

• Mutation-screened addressable population (need for confirmed exon 45 skipping amenable mutations)
• Hospital-administered, weekly chronic treatment (low willingness-to-switch within a patient)
• Payer authorization and evidence thresholds (claims scrutiny around molecular diagnosis and ongoing continuation criteria)
• Competing exon-skipping options for different mutation classes (patients rarely switch across eligibility groups)

What patient populations drive sales volume for exon 45 skipping therapies?

Demand is constrained by the proportion of DMD patients with mutations suitable for exon 45 skipping and by diagnostic workflows. Sales typically track diagnosis prevalence, center adoption, and payer acceptance.

How does AMONDYS 45 compare with other DMD drugs by market structure?

• Different exon targets reduce head-to-head substitution.
• Different payer dynamics emerge based on the perceived clinical evidence for exon skipping versus alternative modalities in the same line-of-care.

When does AMONDYS 45 lose exclusivity and what is the generic or biosimilar entry risk?

Short answer: Casimersen is an antisense oligonucleotide, not a biologic. Generic competition is unlikely to mirror biosimilar timelines, and entry is constrained by complex sequence, manufacturing, and regulatory pathways for oligonucleotide products.

Key entry mechanics for AMONDYS 45 risk planning are:

• Patent estate expiration: determines ability for an FDA-permitted product launch without infringement risk.
• Orange Book status: governs whether “generic” pathways face listed blocking patents.
• Manufacturing and analytical comparability: creates practical barriers even when formal patent barriers decline.

What patents protect AMONDYS 45 and how do they shape timing?

Patent-led exclusivity timing is the dominant variable for any non-infringing follow-on. Because AMONDYS 45 is a branded oligonucleotide with ongoing formulation and method-of-use coverage, the effective exclusivity window often extends beyond the earliest composition date in practice.

What generic entry risks exist for casimersen?

• Sequence-specific identity and oligonucleotide chemistry make “true” generic substitution nontrivial.
• Method-of-use and dosing/administration claims can block even when composition coverage eases.
• Regulatory pathway choices affect launch timing and labeling scope.

What is the Orange Book status of AMONDYS 45 and what does it mean for FDA approval pathways?

Short answer: The Orange Book listing determines whether ANDA-style entry is blocked by unexpired patents and can impose Paragraph IV-style litigation timelines if challengers file.

For market and financial planning, the key questions are:

• Are there listed patents covering casimersen itself (composition)
• Are there listed patents covering method-of-use (exon 45 skipping in DMD, dosing regimens, or patient selection)
• Are there formulation/process patents relevant to manufacturing changes

Because exclusivity and listing status determine challenger incentives, Orange Book mapping is the starting point for forecasting launch risk and settlement likelihood.

How do payer restrictions and reimbursement dynamics affect AMONDYS 45 revenue?

Short answer: AMONDYS 45 revenue is sensitive to payer authorization thresholds, continuation criteria, and documentation requirements for exon 45 amenable mutation status.

Commercial realities for high-cost DMD drugs include:

• Prior authorization anchored to molecular confirmation
• Continuation policies based on functional milestones, survival endpoints, steroid use policies, and payer-specific criteria
• Center-of-excellence purchasing patterns (repeat infusion scheduling and specialty pharmacy logistics)
• Rare-disease budgeting that can drive annual “patient cap” negotiation

What utilization controls reduce spend growth for ultra-orphan DMD therapies?

Payers often:

• limit to patients meeting genetic criteria
• require baseline functional measures
• demand documentation of ongoing eligibility
• negotiate discounts tied to outcomes or continuation

These controls tend to flatten revenue growth even if eligible patient numbers rise modestly.

Which companies manufacture AMONDYS 45 and what is the commercial ownership structure?

Short answer: AMONDYS 45 is marketed by its product holder and specialty commercialization network. The competitive landscape is defined more by DMD pipeline overlap than by direct casimersen substitution.

Market participants typically include:

• the originator for casimersen
• specialty distributors and infusion centers administering dosing
• specialty pharmacy and hub services controlling patient access and documentation flow

What are the main competitive dynamics in DMD that influence AMONDYS 45 financial performance?

Short answer: Competition is indirect because exon targets differ; the most significant threat is substitution pressure from therapies that treat the broader DMD patient population or shift standards of care.

Competitive forces affecting casimersen sales include:

• Exon-skipping therapies for other exons: reduce new patient starts among DMD mutation classes but do not directly take eligible patients with exon 45 mutations.
• Gene therapy and transformative RNA approaches: reduce long-duration recurring spend for eligible future lines-of-care, even if they do not target exon 45.
• Treatment sequencing: payer and clinician preferences shift with new evidence across DMD.

How do exon-skipping competitors influence payer negotiation leverage?

Payers compare clinical rationale, burden of weekly dosing, and evidence endpoints across exon-skipping drugs. Even with different eligibility, comparative cost-effectiveness narratives influence negotiated rebates.

How strong is the patent estate for AMONDYS 45 and what does it imply for long-range revenue?

Short answer: The effective protection for casimersen is driven by the breadth of listed claims around antisense sequence, oligonucleotide chemistry, manufacturing, and method-of-use.

A strong patent estate typically:

• reduces incentives for Paragraph IV challengers until later
• supports higher settlement probability if challenger filings occur
• extends revenue predictability for originator cash flows

What patent types usually dominate oligonucleotide drug protection?

• sequence and hybridization-related composition claims
• conjugation and chemical modification claims (where applicable)
• manufacturing process claims tied to synthesis and purification controls
• method-of-use claims tied to exon skipping in DMD and patient selection

What is the financial trajectory of AMONDYS 45 sales and revenue exposure?

Short answer: AMONDYS 45 revenue trajectory depends on narrow patient penetration and payer continuations more than on broad market expansion. Growth typically comes from new diagnosis capture and center adoption, while decline risks come from payer de-authorization, clinical discontinuations, and protocol shifts.

To forecast revenue trajectory, the market model uses:

1. Eligible prevalence (genetic confirmation rates for exon 45 amenable DMD)
2. Treatment persistence (continuation policies and patient survival)
3. Dose intensity (weekly dosing; disruptions from comorbidities)
4. Price realization (net price after rebates, discounts, and payer contracting)
5. Administrative efficiency (prior auth throughput and hub support)

What levers most affect quarter-to-quarter AMONDYS 45 revenue?

• new starts versus treatment continuation
• payer rule changes that alter eligibility or renewal timing
• channel inventory behavior across specialty pharmacy and infusion centers
• evidence requirements that delay initiation (which can shift revenue between quarters)

How do FDA regulatory milestones and labeling scope affect market size and financials?

Short answer: Label scope limits the total addressable market. For AMONDYS 45, the mutation-specific indication controls market ceiling and payer coverage boundaries.

Commercial implications of regulatory scope include:

• fewer eligible patients compared to broader DMD therapies
• higher burden on documentation systems
• steady revenue once penetration stabilizes, with growth constrained by diagnosis rate rather than market expansion

What settlement dynamics typically shape entry threats for orphan high-cost oligonucleotides?

Short answer: Even for niche orphan drugs, challengers may avoid full litigation until patent cliffs near expiry or if the cost of entry drops due to legal strategy and improved analytics.

Where Paragraph IV challenges occur, settlement terms can include:

• delayed launch dates
• licensing of the challenger’s technology or manufacturing improvements
• market-sharing or supply agreements (less common in very narrow niches)
• dismissal of counterclaims after a payment and/or agreed entry timing

How does AMONDYS 45 pricing and contracting impact net revenue versus list price?

Short answer: Net revenue is typically meaningfully lower than list price due to specialty contracting, payer rebates, and managed care arrangements, with distribution of discounts varying by payer segment and hospital system.

Key pricing mechanics for specialty DMD therapies:

• discounts negotiated by large pharmacy benefit managers
• value-based contracting tied to continuation and functional measures
• carve-outs for infusion centers and specialty pharmacies

These dynamics affect financial trajectory even when patient counts are stable.

Key Takeaways

• AMONDYS 45 commercial performance is driven by a tightly defined exon 45 amenable DMD subgroup, with growth constrained by diagnosis capture and payer authorization.
• Revenue volatility is more likely driven by payer continuation and administrative friction than by competitive substitution within exon 45.
• Generic entry risk is governed by patent estate strength and Orange Book listings, with oligonucleotide complexity creating practical and regulatory barriers.
• Long-range financial trajectory depends on persistence, net price realization, and whether transformative alternatives shift payer and clinician treatment sequencing.

FAQs

1. How does exon 45 mutation prevalence drive AMONDYS 45 patient starts and revenue growth?
2. What payer continuation criteria most commonly reduce or delay AMONDYS 45 utilization in DMD?
3. How does the Orange Book patent listing structure change launch risk for casimersen follow-on products?
4. Do exon-skipping therapies for other DMD exons affect AMONDYS 45 through payer switching or only indirectly via budget constraints?
5. How do manufacturing and analytical comparability requirements affect the feasibility and timeline of non-infringing casimersen launches?

References

1. FDA. Orange Book: Approved Drug Products with Therapeutic Equivalence Evaluations. U.S. Food and Drug Administration.
2. U.S. Patent and Trademark Office (USPTO). Patent assignment and publication databases.